manamed Medical Devices
ManaMed Has Always Got You Covered From Prevention To Recovery!
BAC Medical Marketing (BACMM), and its division, BAC Medical Ancillary Care (BACMAC) are proud to have forged a strategic partnership with ManaMed, a company whose focus is to drive better clinical outcomes with quality patient care and innovative medical devices. ManaMed is a leading provider of orthopaedic braces, rehabilitation products, and portable vascular therapy.
PlasmaFlow
The market leading portable, tubeless, and battery operated portable sequential device. This is the only device that has multiple modalities, verifies pressure, and digitally displays compliance.
The PlasmaFlow is intended to be an easy to use sequential compression system, prescribed by a physician, for use in the home or clinical setting to help prevent the onset of DVT in patients by stimulating blood flow in the extremities (stimulating muscle contractions). This device can be used to:
Product Features
DVT Definitions and Statistics
Deep vein thrombosis (DVT) refers to the development of blood clots, or thrombi, within a deep vein. Typically it occurs in the thigh or calf and can develop after any major surgery. Symptoms may include pain, swelling and skin discoloration, or no signs at all. DVT risk is greatest between two and five days after surgery, with a second peak risk period occurring about 10 days after surgery—after the patient has been discharged. (1) A consecutive pulmonary embolism, or PE, can occur when a clot breaks free and travels through the veins and lodges in the lungs. PE has been reported to occur in over one third of DVT patients and frequently causes sudden death.
The National Center for Health Statistics estimates that DVT is an underlying cause of death for up to 100,000 people annually in the U.S. Estimates place the number of persons affected as high as 900,000. Between 10 and 30 percent will die within one month of diagnosis, and one third will have a recurrence within 10 years. Survivors may have lasting ramifications and chronic respiratory and cardiovascular issues. (3) Without either mechanical or pharmacological prevention, DVT with no obvious symptoms will develop in 40 to 60 percent of patients undergoing total hip and knee arthroplasty. (2) These numbers suggest a very real need for prevention.
1. Deep Vein Thrombosis – OrthoInfo – AAOS. January 2009. Available at: orthoinfo.aaos.org/topic.cfm?topic=a00219
2. The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. 2008. Available at: www.ncbi.nlm.nih.gov/books/NBK44178/
3. Centers for Disease Control. 2015. Available at: www.cdc.gov/ncbddd/dvt/data.html
BAC Medical Marketing (BACMM), and its division, BAC Medical Ancillary Care (BACMAC) are proud to have forged a strategic partnership with ManaMed, a company whose focus is to drive better clinical outcomes with quality patient care and innovative medical devices. ManaMed is a leading provider of orthopaedic braces, rehabilitation products, and portable vascular therapy.
PlasmaFlow
The market leading portable, tubeless, and battery operated portable sequential device. This is the only device that has multiple modalities, verifies pressure, and digitally displays compliance.
The PlasmaFlow is intended to be an easy to use sequential compression system, prescribed by a physician, for use in the home or clinical setting to help prevent the onset of DVT in patients by stimulating blood flow in the extremities (stimulating muscle contractions). This device can be used to:
- Aid in the prevention of DVT
- Enhance blood circulation
- Diminish post-operative pain and swelling
- Reduce wound healing time
- Aid in the treatment and healing of: stasis dermatitis, venous stasis ulcers, arterial and diabetic leg ulcers, chronic venous insufficiency and reduction of edema in the lower limbs.
Product Features
- Portable, lightweight and tubeless
- Long lasting re-chargeable battery. Up to 10 hours of use on one charge
- 2 Modes: Slow inflation and Step-Up Technology which allows the unit to increase pressure in slower increments
- 2 LCD screens to monitor usage and pressure
- Lowers Risk of Venous Thromboembolism (VTE): PlasmaFlow lowers incidence of VTE after major orthopedic surgery compared to pharmacological prophylaxis. VTE is the leading factor for hospital readmission following major orthopedic surgery and the most common preventable cause of hospital death.
- Provides Possible Alternative to Anticoagulants: PlasmaFlow offers physicians another option to help tailor preventative care to patient risk and provides an alternative for patients contraindicated for anticoagulants.
- Provides Convenient Home Therapy: As hospital stays continue to shorten, PlasmaFlow provides a solution for patients to take home and keep. This allows facilities to offer mechanical DVT prophylaxis for the 2-3 weeks patients need it most, without the hassle of renting or servicing equipment.
- Lowers Total Cost: Bundled payment of care initiatives are driving single payment for an orthopedic episode within 30 days of surgery, including costly DVT readmissions. By reducing DVT-related expenses and potentially reducing costs for anticoagulant regimes or compression device rental programs, PlasmaFlow helps reduce the total cost of the episode.
DVT Definitions and Statistics
Deep vein thrombosis (DVT) refers to the development of blood clots, or thrombi, within a deep vein. Typically it occurs in the thigh or calf and can develop after any major surgery. Symptoms may include pain, swelling and skin discoloration, or no signs at all. DVT risk is greatest between two and five days after surgery, with a second peak risk period occurring about 10 days after surgery—after the patient has been discharged. (1) A consecutive pulmonary embolism, or PE, can occur when a clot breaks free and travels through the veins and lodges in the lungs. PE has been reported to occur in over one third of DVT patients and frequently causes sudden death.
The National Center for Health Statistics estimates that DVT is an underlying cause of death for up to 100,000 people annually in the U.S. Estimates place the number of persons affected as high as 900,000. Between 10 and 30 percent will die within one month of diagnosis, and one third will have a recurrence within 10 years. Survivors may have lasting ramifications and chronic respiratory and cardiovascular issues. (3) Without either mechanical or pharmacological prevention, DVT with no obvious symptoms will develop in 40 to 60 percent of patients undergoing total hip and knee arthroplasty. (2) These numbers suggest a very real need for prevention.
1. Deep Vein Thrombosis – OrthoInfo – AAOS. January 2009. Available at: orthoinfo.aaos.org/topic.cfm?topic=a00219
2. The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. 2008. Available at: www.ncbi.nlm.nih.gov/books/NBK44178/
3. Centers for Disease Control. 2015. Available at: www.cdc.gov/ncbddd/dvt/data.html
ManaFlexx & ManaFlexx 2
ManaFlexx & ManaFlexx 2 (the only digital and rechargeable) NMES devices designed for ease of use by eliminating wires or standalone electrodes. These devices are single patient use and are designed for use in the home to treat muscle atrophy due to lack of use or surgery. PDAC approved E0745.
Product Features
The Manaflexx has several advantages over conventional EMS devices.
Doctors prescribe EMS for post-surgical rehab on a regular basis, however it has several applications in everyday Training, Recovery, and Rehabilitation. For training, electrical muscle stimulation with the Manaflexx can provide greater contraction as compared to a normal voluntary contraction, up to 30% higher. Thus more muscles are being used. (i.e. more muscle fiber recruitment).
Another benefit of using the Manaflexx in training is the order of muscle recruitment velocity. Normally, your body would use red fiber (slow twitch) first to do a specified movement, followed by white fiber (fast twitch) when needed. However, with EMS, the order is reversed with the white fibers activating first, thus this type of "muscle training" is beneficial for all speed, power and:
ManaFlexx & ManaFlexx 2 (the only digital and rechargeable) NMES devices designed for ease of use by eliminating wires or standalone electrodes. These devices are single patient use and are designed for use in the home to treat muscle atrophy due to lack of use or surgery. PDAC approved E0745.
- Relaxation of muscle spasms
- Prevention or retardation of disuse atrophy
- Increasing local blood circulation
- Muscle re-education
- Immediate post-surgical stimulation of calf muscles to prevent venous thrombosis
- Maintaining or increasing range of motion
Product Features
The Manaflexx has several advantages over conventional EMS devices.
- Completely portable no wires or bulky devices.
- It can be placed anywhere treatment is desired.
- Battery operated.
- Reusable simply replace pads and batteries.
Doctors prescribe EMS for post-surgical rehab on a regular basis, however it has several applications in everyday Training, Recovery, and Rehabilitation. For training, electrical muscle stimulation with the Manaflexx can provide greater contraction as compared to a normal voluntary contraction, up to 30% higher. Thus more muscles are being used. (i.e. more muscle fiber recruitment).
Another benefit of using the Manaflexx in training is the order of muscle recruitment velocity. Normally, your body would use red fiber (slow twitch) first to do a specified movement, followed by white fiber (fast twitch) when needed. However, with EMS, the order is reversed with the white fibers activating first, thus this type of "muscle training" is beneficial for all speed, power and:
- Provides Possible Alternative to Physical Therapy: ManaFlexx offers physicians another avenue for prescribing NMES.
- Provides Convenient Home Therapy: As hospital stays continue to shorten, physical therapy visits decrease, Manaflexx provides a solution for patients to take home and keep. This allows facilities to offer NMES for up to a month after surgery, without the hassle of renting or servicing equipment.
- Lowers Total Cost: Bundled payment of care initiatives are driving single payment for an orthopedic episode within 90 days of surgery, including physical therapy.
To learn more, please call 800.240.9473 today.
NOTE:
Individual results may vary.
Neither ManaMed or BAC Medical Marketing, nor any of its subsidiaries or divisions dispense medical devices. ManaMed and BAC Medical Marketing provide the information and materials on this site for general information purposes only. You should not rely on the information provided as a substitute for actual professional medical advice, care, or treatment. This website is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment, or services to you or any individual. Please consult your healthcare profession for any information related to treatment, if any, that may be appropriate for you.
Individual results may vary.
Neither ManaMed or BAC Medical Marketing, nor any of its subsidiaries or divisions dispense medical devices. ManaMed and BAC Medical Marketing provide the information and materials on this site for general information purposes only. You should not rely on the information provided as a substitute for actual professional medical advice, care, or treatment. This website is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment, or services to you or any individual. Please consult your healthcare profession for any information related to treatment, if any, that may be appropriate for you.
